Tags

Type your tag names separated by a space and hit enter

Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
Am Heart J. 2007 Jul; 154(1):94-101.AH

Abstract

BACKGROUND

Erectile dysfunction (ED) is a common disorder in middle-aged men and is significantly influenced by cardiovascular risk factors (CVRFs) and cardiovascular disease. The substudy of the ONTARGET/TRANSCEND trials evaluates the relationship of erectile function to baseline characteristics and current treatment in cardiovascular high-risk patients who have been enrolled in these trials. The effects of treatment with telmisartan and ramipril, alone or in combination, including a telmisartan versus placebo arm will be determined prospectively during a follow-up of 4 years.

METHODS

One thousand three hundred fifty-seven patients were evaluated in 13 countries at baseline, 2 years, and 4 years, with ED determined using the ED score of the Cologne Male Survey (Kölner [Cologne] Evaluation of Erectile Dysfunction) and the 5-item International Index of Erectile Function. Erectile dysfunction scores were related to CVRF and the use of cardiovascular drugs.

RESULTS

Prevalence of ED was 50.7% (Kölner [Cologne] Evaluation of Erectile Dysfunction) and 54.3% (5-item International Index of Erectile Function), respectively, with a decline of sexual activity after the diagnosis of cardiovascular disease. In multivariate analysis, diabetes mellitus (P < .00001), stroke (P = .00026), pelvic surgery (P = .025), and age of >65 years (P < .00001) correlated with the degree of ED. No significant associations were observed for cholesterol levels, hypertension, and smoking status as well as current treatment with angiotensin-converting enzyme inhibitors, angiotensin I antagonists, diuretics, beta-blockers, or calcium-channel blockers.

CONCLUSIONS

The ONTARGET/TRANSCEND-ED substudy shows a significant influence of cardiovascular disease on erectile function. In contrast to prior smaller studies, drug therapy and CVRF seem to play a minor role in cardiovascular high-risk patients. Follow-up data will provide information whether angiotensin-converting enzyme inhibitors, angiotensin I antagonists, or a combination thereof are able to improve erectile function.

Authors+Show Affiliations

Klinik für Innere Medizin III des Universitätsklinikum des Saarlandes, Saarland, Homburg, Germany. boehm@med-in.uni-saarland.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

17584560

Citation

Böhm, Michael, et al. "Sexual Function, Satisfaction, and Association of Erectile Dysfunction With Cardiovascular Disease and Risk Factors in Cardiovascular High-risk Patients: Substudy of the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects With Cardiovascular Disease (ONTARGET/TRANSCEND)." American Heart Journal, vol. 154, no. 1, 2007, pp. 94-101.
Böhm M, Baumhäkel M, Probstfield JL, et al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J. 2007;154(1):94-101.
Böhm, M., Baumhäkel, M., Probstfield, J. L., Schmieder, R., Yusuf, S., Zhao, F., & Koon, T. (2007). Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). American Heart Journal, 154(1), 94-101.
Böhm M, et al. Sexual Function, Satisfaction, and Association of Erectile Dysfunction With Cardiovascular Disease and Risk Factors in Cardiovascular High-risk Patients: Substudy of the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects With Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J. 2007;154(1):94-101. PubMed PMID: 17584560.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). AU - Böhm,Michael, AU - Baumhäkel,Magnus, AU - Probstfield,Jeffrey L, AU - Schmieder,Roland, AU - Yusuf,Salim, AU - Zhao,Feng, AU - Koon,Teo, AU - ,, PY - 2006/12/18/received PY - 2007/03/15/accepted PY - 2007/6/23/pubmed PY - 2007/7/3/medline PY - 2007/6/23/entrez SP - 94 EP - 101 JF - American heart journal JO - Am. Heart J. VL - 154 IS - 1 N2 - BACKGROUND: Erectile dysfunction (ED) is a common disorder in middle-aged men and is significantly influenced by cardiovascular risk factors (CVRFs) and cardiovascular disease. The substudy of the ONTARGET/TRANSCEND trials evaluates the relationship of erectile function to baseline characteristics and current treatment in cardiovascular high-risk patients who have been enrolled in these trials. The effects of treatment with telmisartan and ramipril, alone or in combination, including a telmisartan versus placebo arm will be determined prospectively during a follow-up of 4 years. METHODS: One thousand three hundred fifty-seven patients were evaluated in 13 countries at baseline, 2 years, and 4 years, with ED determined using the ED score of the Cologne Male Survey (Kölner [Cologne] Evaluation of Erectile Dysfunction) and the 5-item International Index of Erectile Function. Erectile dysfunction scores were related to CVRF and the use of cardiovascular drugs. RESULTS: Prevalence of ED was 50.7% (Kölner [Cologne] Evaluation of Erectile Dysfunction) and 54.3% (5-item International Index of Erectile Function), respectively, with a decline of sexual activity after the diagnosis of cardiovascular disease. In multivariate analysis, diabetes mellitus (P < .00001), stroke (P = .00026), pelvic surgery (P = .025), and age of >65 years (P < .00001) correlated with the degree of ED. No significant associations were observed for cholesterol levels, hypertension, and smoking status as well as current treatment with angiotensin-converting enzyme inhibitors, angiotensin I antagonists, diuretics, beta-blockers, or calcium-channel blockers. CONCLUSIONS: The ONTARGET/TRANSCEND-ED substudy shows a significant influence of cardiovascular disease on erectile function. In contrast to prior smaller studies, drug therapy and CVRF seem to play a minor role in cardiovascular high-risk patients. Follow-up data will provide information whether angiotensin-converting enzyme inhibitors, angiotensin I antagonists, or a combination thereof are able to improve erectile function. SN - 1097-6744 UR - https://www.unboundmedicine.com/medline/citation/17584560/Sexual_function_satisfaction_and_association_of_erectile_dysfunction_with_cardiovascular_disease_and_risk_factors_in_cardiovascular_high_risk_patients:_substudy_of_the_ONgoing_Telmisartan_Alone_and_in_Combination_with_Ramipril_Global_Endpoint_Trial/Telmisartan_Randomized_AssessmeNT_Study_in_ACE_INtolerant_Subjects_with_Cardiovascular_Disease__ONTARGET/TRANSCEND__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-8703(07)00246-3 DB - PRIME DP - Unbound Medicine ER -